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Introduction
Statins are first-line therapy for reducing atherosclerotic
cardiovascular disease (ASCVD) risk.1 Several international
guidelines recommend high-risk and very high-risk patients
achieve low-density lipoprotein cholesterol (LDL-C) levels
<100mg/dL and <70mg/dL, respectively.2–4 However,
many patients fail to reach expected or recommended
LDL-C levels on statin therapy. For example, a 2012
cross-sectional survey reported that approximately two-
thirds of high-risk patients on statin monotherapy for
>90 days did not achieve LDL-C levels <100mg/dL, and
only an estimated quarter of these high-risk patients had
LDL-C levels <70mg/dL.5 Surveys from other countries
show similar results.6–9 A European study found that of
dyslipidemic patients receiving lipid-lowering drugs, fewer
than half achieved LDL-C levels <100mg/dL.6 In addition,
studies have shown that approximately 80% of patients with
heterozygous familial hypercholesterolemia (heFH) do not
achieve LDL-C levels <100mg/dL from a statin.10,11
In clinical practice, patients are typically started on
a statin of moderate intensity, where the daily dose is
expected to lower LDL-C levels by approximately 30% to
<50%.12,13 However, the recent 2013 American College of
Cardiology/American Heart Association Guideline on the
Treatment of Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults recommended high-intensity
statin therapy that lowers LDL-C by ≥50% for higher-
risk patients, such as those with clinical ASCVD, diabetes
mellitus (with an estimated 10-year ASCVD risk≥7.5%), and
for LDL-C ≥190mg/dL.1
If patients fail to reach target LDL-C levels or achieve the
expected therapeutic response on their initial statin therapy,
the treating clinician currently has the options of increasing
the statin dose or switching to a more effective LDL-C–
lowering statin; and for those unable to tolerate high-
intensity statins, nonstatin therapy may be added to further
lower LDL-C (most commonly ezetimibe).1 Given the
degree to which hypercholesterolemia remains poorly con-
trolled, even with statin therapy, high–CV-risk patients may
benefit from more intensive cholesterol-lowering therapy
options.1,5,14
Alirocumab (formerly REGN727/SAR236553; Sanofi-
Regeneron) is a fully human monoclonal antibody currently
in phase 3 development for LDL-C lowering. In phase 2 trials
in patients receiving concomitant statin or statin+ ezetimibe
therapy (NCT01288443, NCT01266876, and NCT01288469),
alirocumab significantly reduced mean LDL-C levels by
up to 72.4% and also reduced levels of apolipoprotein B,
total cholesterol, non–high-density lipoprotein cholesterol
(non–HDL-C), lipoprotein(a), and triglycerides (TG), and
moderately increased HDL-C and apolipoprotein A-1
levels.15–17 Themost common treatment-emergent adverse
event (TEAE; defined as an adverse event (AE) occurring
in the time period from first study treatment dosing to 70
days following the last study treatment dosing) in phase
2 trials was injection-site reaction, which was generally of
mild intensity and short duration.15–17
The OPTIONS I and II studies (NCT01730040 and
NCT01730053, respectively) will compare the lipid-lowering
efficacy and safety of alirocumab with various therapeutic
choices in patients at high CV risk on atorvastatin 20mg or
40mg daily or rosuvastatin 10mg or 20mg daily and who
had LDL-C levels above prespecified levels of ≥70mg/dL
or ≥100mg/dL. The OPTIONS studies are part of the 14-
study ODYSSEY alirocumab phase 3 program that includes
more than 23 500 patients in >2000 centers globally; this
also comprises a large CV outcomes trial evaluating the
long-term impact of alirocumab and lower levels of LDL-C
on the occurrence of CV events in 18 000 patients after a
recent (<52weeks) acute coronary syndrome event. Here
we describe theOPTIONS I and II study designs and discuss
how these studies may inform clinical management.
Methods
Overview
The OPTIONS I and OPTIONS II clinical trials are phase 3,
multinational,multicenter, randomized, double-blind, active-
comparator, and parallel-group studies that were conducted
across North America, Europe, and Australia. OPTIONS I
commenced October 2012, was conducted at 91 sites, and
completed in June 2014. OPTIONS II commenced Novem-
ber 2012, was conducted at 90 sites, and also completed in
June 2014.
The trials were performed in accordance with the ethi-
cal principles that have their origin in the Declaration of
Helsinki and all applicable amendments laid down by the
World Medical Assemblies and the International Confer-
ence on Harmonisation Good Clinical Practice Guidelines.
Institutional review board or independent ethics commit-
tee approval of the protocols and informed consent forms
were obtained from each study site, and written informed
consent was obtained from all patients.
Study Objectives
The primary objective of OPTIONS I is to compare the
LDL-C–lowering efficacy and safety of adding alirocumab
to the most commonly used doses of atorvastatin (20mg
or 40mg) with the strategies of adding ezetimibe, doubling
the atorvastatin dose, or switching from atorvastatin 40mg
to rosuvastatin 40mg. Patients were receiving either
atorvastatin 20mg or 40mg at baseline and had received
this stable dose for ≥4weeks.
OPTIONS II focuses on patients receiving rosuvastatin.
Here, the LDL-C–lowering efficacy and safety of adding
alirocumab to rosuvastatin will be compared with adding
ezetimibe or doubling the rosuvastatin dose. Patients were
receiving either rosuvastatin 10mg or 20mg at baseline and
had received the same dose for ≥4weeks.
Both studies are evaluating these treatment options in
high–CV-risk patients whose LDL-C levels were greater
than or equal to the prespecified levels of 70mg/dL or
100mg/dL on their existing statin dose (Table 1). The levels
were based on guidelines current at the time the protocols
were finalized.12,13 In both studies, patients could have
been on other lipid-lowering therapies (LLTs), except for
ezetimibe or statins other than atorvastatin (for OPTIONS
I) and rosuvastatin (OPTIONS II).
Randomization
In OPTIONS I, depending on whether they were receiving
20mg or 40mg atorvastatin daily at baseline, patients were
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Table 1. Key Inclusion and Exclusion Criteria
Inclusion Criteria
Patients with hypercholesterolemia (non-FH or heFH) at high CV risk with LDL-C levels above those prespecified and receiving:
OPTIONS I OPTIONS II
Atorvastatin (20mg or 40mg daily), with or without other LLT
(excluding ezetimibe), for ≥4weeks prior to screening visit
Rosuvastatin (10mg or 20mg daily), with or without other LLT (excluding
ezetimibe), for ≥4weeks prior to screening visit
Baseline Entry Criteria
Inclusion criteria
Patients with LDL-C levels≥70mg/dL (≥1.81mmol/L) at the screening visit with a history of documented CVD; patients with a history of documented CHD,
non-CHD CVD, or DM with target organ damage
Patients with LDL-C levels ≥100mg/dL (≥2.59mmol/L) at the screening visit in patients without history of documented CVD; patients must also have
heFH, or have non-FH, without CHD or non-CHD CVD, but with calculated 10-year fatal CVD risk SCORE ≥5%, or with moderate CKD, or with DM but no
target organ damage
Exclusion criteria
Age<18 years
Fasting serum TG>400mg/dL (>4.52mmol/L) during the screening period
Currently taking ezetimibe, or had received ezetimibe, within 4 weeks of the screening visit
Uncontrolled endocrine disease known to influence serum lipids
OPTIONS I OPTIONS II
Currently taking a statin that is not atorvastatin daily at 20mg or
40mg
Currently taking a statin that is not rosuvastatin daily at 10mg or 20mg
Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; DM, diabetes mellitus;
heFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; non-FH, non-familial
hypercholesterolemia; SCORE, systematic coronary risk evaluation; TG, triglycerides.
randomized to 1 of 3 (20mg atorvastatin daily at baseline)
or 1 of 4 (40mg atorvastatin daily at baseline) treatment
arms (Figure 1). In OPTIONS II, patients receiving 10mg
or 20mg rosuvastatin daily at baseline were randomized to
1 of 3 treatment arms (Figure 1). Screening was stopped
once approximately 5% to 10% more patients than specified
by the protocol were projected to be randomized for a given
baseline statin regimen.
For each study, and within each baseline statin regimen,
randomization was stratified according to whether or not
the patient has a history of either myocardial infarction or
ischemic stroke. This stratification contributes to balance
patient history of these major atherosclerosis-associated CV
events in treatment arms across the clinical trials program.
Study Endpoints and Assessments
The primary endpoint for both OPTIONS I and II is the
difference in percent change in calculated LDL-C from
baseline to week 24 (Table 2) in the alirocumab arm
vs control arms. The LDL-C was calculated using the
Friedewald formula at screening and at all time points
during the double-blind treatment periods. If TGs exceeded
400mg/dL (4.52mmol/L), then the central laboratory
reflexively measured LDL-C (via the β quantification
method) rather than calculating it. TheLDL-Cwasmeasured
(via the β quantification method) at week 0 and week 24.
For both studies, there are 2 baseline statin regimens
(atorvastatin 20mg or 40mg in OPTIONS I, rosuvastatin
10mg or 20mg in OPTIONS II), and there are 3 or
4 treatment arms within each regimen (Figure 1). The
primary analysis will compare the difference in percent
change in LDL-C between the alirocumab arm and each
of the comparator arms. For example, in OPTIONS I, for
the atorvastatin 20-mg regimen, there will be 2 pairs of
comparisons: The alirocumab arm will be compared with
the ezetimibe arm, and the alirocumab arm will also be
compared with the arm doubling the atorvastatin dose to
40mg. Key secondary endpoints are summarized in Table 2.
On-site patient assessments took place at randomization
and then at weeks 4, 8, 12, 16, and 24, and at the end-of-study
visit, week 32.
Safety
Safety events (AEs [including adjudicated CV events cate-
gorized as coronary heart disease, death, nonfatal myocar-
dial infarction, fatal and nonfatal ischemic stroke, unsta-
ble angina requiring hospitalization, and congestive heart
failure requiring hospitalization], injection-site reactions,
laboratory data [blood biochemistry, hematology, and uri-
nalysis], vital signs and electrocardiogram) were assessed
throughout the study. The development of anti-alirocumab
antibodies was also monitored.
Clin. Cardiol. 37, 10, 597–604 (2014) 599
J. Robinson et al: ODYSSEY OPTIONS studies
Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI:10.1002/clc.22327© 2014 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
(A)
(B)
Figure 1. (A) Study design for OPTIONS I. (B) Study design for OPTIONS II. *75mg SC Q2W with titration (as necessary) to 150mg SC Q2W. Abbreviations:
NCEP ATP III TLC, National Cholesterol Education Program–Adult Treatment Panel III Therapeutic Lifestyle Changes; Q2W, every 2 weeks; R, randomization;
SC, subcutaneous.
Inclusion Criteria
In both studies, entry criteria included a lower limit for
baseline LDL-C levels depending on risk category for CVD
(Table 1). For patients with heFH, the diagnosis must
have been made either by genotyping or clinical criteria.
For those patients not genotyped, the clinical criteria were
based on either the Simon Broome criteria with criteria for
definite heFH18 or the World Health Organization/Dutch
Lipid Network criteria with a score of >8 points.19
Exclusion Criteria
Thekeyexclusion criteriawere age<18 years; fasting serum
TG >400mg/dL (>4.52mmol/L) during the screening
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Table 2. Key Study Endpoints (Common to Both Studies)
Primary endpoint
Difference in % change in calculated LDL-C from baseline to week 24 in the alirocumab vs the control arms in the ITT population, using all LDL-C values
regardless of adherence to treatment (ITT estimand)
Key secondary endpoints (unless otherwise noted, all are the difference in % change in lipid parameter in the alirocumab vs control arms):
Calculated LDL-C from baseline to week 24 in the mITT population, using all LDL-C values during the efficacy treatment period (on-treatment estimand)
Calculated LDL-C from baseline to week 12 (ITT estimand)
Calculated LDL-C from baseline to week 12 (on-treatment estimand)
Apo B from baseline to week 24 (ITT estimand)
Apo B from baseline to week 24 (on-treatment estimand)
Non–HDL-C from baseline to week 24 (ITT estimand)
Non–HDL-C from baseline to week 24 (on-treatment estimand)
Total cholesterol from baseline to week 24 (ITT estimand)
Apo B from baseline to week 12 (ITT estimand)
Non–HDL-C from baseline to week 12 (ITT estimand)
Total cholesterol from baseline to week 12 (ITT estimand)
Calculated LDL-C from baseline to week 52 (ITT estimand)
Proportion of very high-CV-risk patients reaching calculated LDL-C<70mg/dL (1.81mmol/L) or high-CV-risk patients reaching calculated LDL-C
<100mg/dL (2.59mmol/L) at week 24 (ITT estimand)
Proportion of very high-CV-risk patients reaching calculated LDL-C<70mg/dL (1.81mmol/L) or high-CV-risk patients reaching calculated LDL-C
<100mg/dL (2.59mmol/L) at week 24 (on-treatment estimand)
Proportion of patients reaching LDL-C<70mg/dL (1.81mmol/L) at week 24 (ITT estimand)
Proportion of patients reaching LDL-C<70mg/dL (1.81mmol/L) at week 24 (on-treatment estimand)
Lp(a) from baseline to week 24 (ITT estimand)
HDL-C from baseline to week 24 (ITT estimand)
Fasting TG from baseline to week 24 (ITT estimand)
Apo A-1 from baseline to week 24 (ITT estimand)
Lp(a) from baseline to week 12 (ITT estimand)
HDL-C from baseline to week 12 (ITT estimand)
Fasting TG from baseline to week 12 (ITT estimand)
Apo A-1 from baseline to week 12 (ITT estimand)
Abbreviations: Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; ITT, intent-to-treat; LDL-C, low-density lipoprotein cholesterol; Lp(a),
lipoprotein(a); mITT, modified intent-to-treat; TG, triglycerides.
period; patients receiving a statin that was not atorvastatin
20mg or 40mg daily (OPTIONS I) or not rosuvastatin 10mg
or 20mg daily (OPTIONS II); patients receiving ezetimibe
within 4 weeks prior to the screening visit; and uncontrolled
endocrine disease known to influence serum lipids (Table 1;
for a full list of inclusion and exclusion criteria, see
Supporting Information, Supplementary Methods, in the
online version of this article).
Study Procedures
Both studies consisted of 3 periods: a 2-week to 6-week
screening period, a 24-week double-blind treatment period,
and an 8-week follow-up period. The screening period
included an intermediate visit during which the patient
or caregiver was trained to self-inject/inject. Patients on a
stable atorvastatin (OPTIONS I) or rosuvastatin (OPTIONS
II) dose for ≥4weeks before the screening visit 1 were
screened for study eligibility. During screening and at the
discretion of the investigator, patients not on a stable dose
of atorvastatin (20mg or 40mg; OPTIONS I) or rosuvastatin
(10mg or 20mg; OPTIONS II) for 4 weeks; patients
being switched to atorvastatin (OPTIONS I) or rosuvastatin
(OPTIONS II); or patients not on a statin but who should
have been, according to local guidance, received open-label
atorvastatin (20mg or 40mg; OPTIONS I) or rosuvastatin
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(10mg or 20mg; OPTIONS II) for a 4-week run-in period
between the prescreening visit 1a (day −42) and visit 1. The
run-in dose of atorvastatin or rosuvastatin was based on the
judgment of the study physician.
At randomization, treatment kit numbers were allocated
using a centralized treatment allocation system, either an
interactive voice-response system or an interactive Web-
response system, depending on the site preference. Study
patients, principal investigators, and study-site personnel
were blinded to all randomization assignments throughout
the duration of the study. All lipid and antidrug antibody
results collected after randomization were masked.
Each eligible patient received a single, subcutaneous, 1-
mL injection by prefilled pen every 2 weeks (Q2W) (aliro-
cumab or placebo-alirocumab) and 2 oral-blinded medica-
tions daily (a statin [atorvastatin or rosuvastatin] and ezetim-
ibe or placebo-ezetimibe). The first injection of alirocumab
or placebo-alirocumab was administered at the clinical site
(week 0), after study assessments were completed, and
as soon as possible after the patient was randomized into
the study. The patient/caregiver administered subsequent
autoinjections outside of the clinic, at a patient-preferred
location, on weeks 2, 4, 6, 8, and 10.
At week 12, based on their week 8 LDL-C level and
baseline CV risk, patients randomized to alirocumab may,
in a blinded manner, have had their dose increased from
75mg Q2W to 150mg Q2W. To maintain blinding, lipid
values obtained at week 8 for the purpose of up-titration
occurred in an automated process and were not commu-
nicated to investigators or patients. Patients with baseline
LDL-C levels ≥70mg/dL and documented CVD continued
to receive alirocumab 75mg Q2W if their week 8 LDL-C
level was <70mg/dL (1.81mmol/L); otherwise, they were
dose up-titrated to receive alirocumab 150mg Q2W (also
via a 1-mL autoinjection) if their week 8 LDL-C level was
≥70mg/dL (1.81mmol/L). Patients with baseline LDL-C
levels ≥100mg/dL without documented CVD continued
to receive alirocumab 75mg Q2W if their week 8 LDL-C
level was<100mg/dL (2.59mmol/L); otherwise, they were
dose up-titrated to alirocumab 150mg Q2W if their week
8 LDL-C level was ≥100mg/dL (2.59mmol/L). Autoinjec-
tions continued to be administered atweeks 12, 14, 16, 18, 20,
and 22; the last dose of daily oral study drugs was adminis-
tered at week 24.
So as not to interfere with the study drug or serum
lipids, the following concomitant LLTs were prohibited from
the initial screening visit until the end of the study visit:
statins other than atorvastatin and rosuvastatin (provided as
blinded medications), ezetimibe (other than that provided
as blinded medication), fibrates other than fenofibrate,
and red yeast rice products. Lipid-lowering therapies that
were allowed as background therapy throughout the study
included fish oils with omega-3 fatty acids, fenofibrate,
bile acid-binding sequestrants, and niacin. Doses of these
medications were stable for ≥4weeks before screening
(≥6weeks for fenofibrate) and were to remain stable for the
duration of the study.
Throughout the studies, patients were asked to follow
a stable, National Cholesterol Education Program–Adult
Treatment Panel III Therapeutic Lifestyle Changes
(NCEP-ATP III TLC) diet or equivalent diet from screening
to the end-of-study visit. At the end of the 24-week treatment
period, patients entered an 8-week follow-up period.
Statistical Design and Analysis
The planned patient populations were 350 and 300 for
OPTIONS I and OPTIONS II, respectively. For efficacy
comparisons, it was estimated that a total sample size of
50 patients (OPTIONS I) or 47 patients (OPTIONS II) per
arm would have 90% power to detect a difference in means
of ≥20% in any one pairwise comparison (ie, alirocumab
mean= 50% and control mean= 30%), assuming that the
common standard deviation (SD) is 25 and that all 50 or
47 patients, respectively, are evaluable (for full statistical
methods, see Supporting Information, Supplementary
Methods, in the online version of this article).
In both OPTIONS I and II, the primary efficacy analysis
population is the intent-to-treat population comprising all
randomized patients with ≥1 baseline calculated LDL-C
value available and ≥1 calculated LDL-C value available
at one of the planned time points from weeks 4 and 24,
regardless of treatment adherence.
The percent change in calculated LDL-C from baseline
to week 24 will be analyzed using a mixed-effect model
with repeated measures (MMRM) approach to account for
missing data (see Supporting Information, Supplementary
Methods, in the online version of this article).20,21
Treatment differences between alirocumab-treated patients
and patients treated with active comparators will be
estimated and tested through pairwise comparisons within
each baseline statin regimen (see Supporting Information,
Supplementary Methods, in the online version of this
article). Secondary endpoints will be tested with a similar
approach (see Supporting Information, Supplementary
Methods, in the online version of this article).
Safety events will be reported using descriptive statistics,
based on the safety population (all randomized patients who
received ≥1 dose or partial dose of study treatment). The
safety analysis will focus on the TEAE period, defined as
the time from the first double-blind dose to 70 days after the
last double-blind dose of the investigational drug.
Results
Three hundred and fifty-five patients were randomized
into OPTIONS I, and 305 patients were randomized into
OPTIONS II. Baseline characteristics and lipid parameters
are reported in Table 3. Briefly, 65.1% and 61.3% of patients
were male in the OPTIONS I and OPTIONS II studies,
respectively. The average age was 63 years in OPTIONS I
and 61 years inOPTIONS II, and patients hadCV risk factors
such as coronary heart disease (59.4% and 63.0%), diabetes
mellitus (50.1% and 42.0%), and hypertension (78.3% and
72.5%) in OPTIONS I and II, respectively. In OPTIONS I,
the average baseline LDL-C level was 105.1mg/dL, and in
OPTIONS II it was 111.3mg/dL.
Discussion
Evidence from meta-analyses and well-controlled random-
ized trials of statin therapy show that reducing LDL-C is
associated with a significant reduction in risk of CV events
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Table 3. Baseline Characteristics and Lipid Parameters
OPTIONS I,
n= 355
OPTIONS II,
n= 305
Characteristic
Age (SD), y 62.9 (10.2) 60.9 (10.3)
Male, n (%) 231 (65.1) 187 (61.3)
Race, n (%)
White 306 (86.2) 256 (83.9)
Black 38 (10.7) 27 (8.9)
Other 11 (3.1) 22 (7.2)
BMI (SD), kg/m2 31.0 (6.4) 31.3 (6.6)
CHD, n (%) 211 (59.4) 192 (63.0)
DM, n (%) 178 (50.1) 128 (42.0)
Hypertension, n (%) 278 (78.3) 221 (72.5)
Current smoker, n (%) 66 (18.6) 56 (18.4)
Lipid parameters
LDL-C (SD), mg/dL 105.1 (34.1) 111.3 (39.0)
TC (SD), mg/dL 182.0 (39.0) 191.1 (44.7)
HDL-C (SD), mg/dL 48.7 (13.4) 50.0 (13.1)
Fasting TG, median (Q1:Q3),
mg/dL
140.7 (89.0:175.0) 128.0 (92.0:185.0)
Non–HDL-C (SD), mg/dL 133.3 (38.8) 141.1 (43.4)
Apo B (SD), mg/dL 90.8 (23.2) 95.3 (24.1)
Apo A-1 (SD), mg/dL 144.2 (23.8) 146.2 (25.0)
Lp(a), median (Q1:Q3),
mg/dL
44.8 (8.0:68.0) 28.0 (11.0:79.0)
Abbreviations; Apo, apolipoprotein; BMI, body mass index; CHD,
coronary heart disease; DM, diabetes mellitus; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
Lp(a), lipoprotein(a); SD, standard deviation; TC, total cholesterol;
TG, triglycerides.
and mortality.1,22–27 Despite the availability of statins and
other LLTs, many patients with hypercholesterolemia and
high CV risk are not achieving LDL-C levels <100mg/dL
or <70mg/dL.1,5–8,10,11
In clinical practice, patients tend to be initiated on
low- to moderate-intensity statin therapy (a daily dose
that provides an approximate <30% to 30% to 50% LDL-C
reduction, respectively), with up-titration or switching to a
higher-intensity statin regimen (a daily dose that provides
an approximate ≥50% LDL-C reduction) as necessary for
individuals not achieving LDL-C targets or the expected
therapeutic response from the initial dose of statin.12,13
For high-risk individuals who require greater LDL-C
lowering than that achieved with statin therapy alone, some
guidelines recommend combination of statin therapy with
≥1 other LLT. Guidelines also recommend the use of other
LLTs for individuals who are unable to tolerate a statin
dose sufficient to reduce LDL-C to target levels or who are
unable to tolerate high-intensity statin therapy or achieve
the desired percent reduction in LDL-C.1,12,13
Despite these guidelines, however, studies conducted in
real-world settings suggest that the percentage of patients
achieving recommended LDL-C levels is not optimal and
can be improved.6–8,28 For example, an observational
study assessing treatment practice patterns in high–CV-
risk patients on statin monotherapy found that although
greater LDL-C reductions were seen in patients who
received add-on ezetimibe therapy or underwent a statin
dose up-titration, approximately 30% of these patients were
not achieving LDL-C levels <70mg/dL,29 suggesting that
currently available treatment options are not sufficient for
some higher-risk patients. Furthermore, recent evidence
also suggests doubling the dose to that of a high-intensity
statin may provide minimal benefit from additional LDL-C
lowering.30 For example, it was calculated that increasing
the dose from 40mg to 80mg of atorvastatin may result
in only an approximate 2% reduction in the risk of clinical
events.30 Overall, whereas statins have been shown to be
efficacious in lowering LDL-C, patients at high CV risk may
benefit from additional, more intensive LLTs to help them
achieve their LDL-C goals.
A recent study conducted with another proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in
patients with hypercholesterolemia and on stable, daily,
moderate-intensity (10mg atorvastatin, 40mg simvastatin,
or 5mg rosuvastatin) or high-intensity (80mg atorvastatin
or 40mg rosuvastatin) statin therapy, assessed the LDL-
C–lowering effect of added evolocumab or ezetimibe.31
Findings showed that the addition of evolocumab resulted
in additional LDL-C lowering.31 The ODYSSEY OPTIONS
studies assess the lipid-lowering efficacy and safety of
alirocumabas add-on therapy in comparisonwith the current
clinical strategies that exist for high–CV-risk patients whose
LDL-C levels are not sufficiently reduced with the most
commonly used atorvastatin or rosuvastatin doses. The
studies are designed to answer practical questions facing
the clinician: Which clinical strategy provides the best com-
bination of LDL-C–lowering efficacy and safety/tolerability?
Add alirocumab? Increase the statin dose or switch to
another statin, or add ezetimibe? The study design also pro-
vides flexibility in the alirocumab dosing regimen, which in
turn allows for individualized therapy based on the degree of
LDL-C reduction required to achieve the desired treatment
response.
Whether additional LDL-C lowering in patients optimally
treated with statins will further reduce CV events is under
evaluation in ongoing trials of ezetimibe as well as a
number of PCSK9 monoclonal antibodies. The ODYSSEY
OUTCOMES trial is evaluating alirocumab in patients with
acute coronary syndromes.
In conclusion, the ODYSSEY OPTIONS studies aim to
provide further data regarding the efficacy of alirocumab to
reduce LDL-C levels in patients with hypercholesterolemia
at high CV risk, in particular those patients who are not
achieving specific LDL-C levels with the most commonly
used atorvastatin or rosuvastatin doses. This trial will also
evaluate the safety and tolerability of alirocumab in a larger
patient population over 24 weeks.
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